| Literature DB >> 26498925 |
Brett Williams1, Ted Brown2, Shane Costello3.
Abstract
BACKGROUND: It is important that scales exhibit strong measurement properties including those related to the investigation of issues that impact evidence-based practice. The validity of the Barriers to Research Utilization Scale (BARRIERS Scale) has recently been questioned in a systematic review. This study investigated the dimensional structure and stability of the 28 item BARRIERS Scale when completed by three groups of participants from three different cross-cultural environments.Entities:
Mesh:
Year: 2015 PMID: 26498925 PMCID: PMC4619557 DOI: 10.1186/s13104-015-1579-9
Source DB: PubMed Journal: BMC Res Notes ISSN: 1756-0500
Participant demographic data (n = 696)
| Frequencya | Percentage | |
|---|---|---|
| Gender | ||
| Female | 519 | 74.60 |
| Male | 177 | 25.43 |
| Total | 696 | 100.03 |
| Age (years) | ||
| 20–29 years | 267 | 38.36 |
| 30–39 years | 268 | 38.51 |
| 40–49 years | 97 | 13.94 |
| 50–59 years | 52 | 7.50 |
| 60+ years | 5 | 0.72 |
| Total | 689 | 99.03 |
| Country of residence | ||
| Australia (response rate 45 %) | 137 | 19.68 |
| United Kingdom (response rate 30 %) | 144 | 20.70 |
| Taiwan (response rate 91 %) | 413 | 59.34 |
| Other | 2 | 0.29 |
| Total | 696 | 100.01 |
| Highest level of occupational therapy (OT) qualification obtained | ||
| Diploma/certificate in OT | 79 | 11.35 |
| Bachelors degree in OT | 540 | 77.59 |
| Entry level masters degree in OT | 8 | 1.15 |
| Course work/research masters in OT | 58 | 8.33 |
| Research doctorate in OT | 10 | 1.44 |
| Total | 695 | 99.86 |
| Employment status | ||
| Full-time between 20 and 40 h per week | 594 | 85.34 |
| Part-time less than 20 h per week | 69 | 9.91 |
| Student/postgraduate student | 12 | 1.72 |
| Non-practicing | 10 | 1.44 |
| Other | 10 | 1.44 |
| Total | 695 | 99.86 |
| Current position | ||
| OT clinician working for an employer | 563 | 80.90 |
| Private practitioner | 46 | 6.61 |
| OT manager/administrator | 36 | 5.17 |
| Academic faculty/educator | 14 | 2.01 |
| Researcher | 7 | 1.01 |
| Consultant | 2 | 0.29 |
| Administrative coordinator/supervisor/case-manager | 9 | 1.30 |
| Other | 18 | 2.59 |
| Total | 695 | 99.88 |
aThe total number of participants included in the study was 696. However the ‘total’ categories do vary as some participants left some of the demographic questions blank
Initial PCA loadings with Procrustes transformation by country
| Item | Australia | United Kingdom | Taiwan | Procrustes congruence | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | AUS | UK | TAI | |
| ADOPT1 |
| 0.19 | 0.09 | −0.03 |
| 0.27 | 0.12 | 0.34 |
| 0.22 | 0.18 | 0.27 | 0.96 | 0.88 | 0.89 |
| ADOPT2 |
| 0.26 | 0.06 | 0.07 |
| 0.22 | 0.04 | 0.39 |
| 0.22 | 0.22 | 0.26 | 0.96 | 0.90 | 0.87 |
| ADOPT3 |
| 0.30 | 0.13 | −0.07 |
| 0.20 | 0.22 | 0.29 |
| 0.25 | 0.23 | 0.18 | 0.90 | 0.85 | 0.88 |
| ADOPT4 |
| −0.17 | 0.04 | 0.11 |
| −0.02 | −0.09 | −0.16 |
| 0.07 | 0.26 | 0.23 | 0.89 | 0.89 | 0.79a |
| ADOPT5 |
| 0.25 | 0.12 | 0.06 |
| 0.35 | 0.14 | 0.26 |
| 0.23 | 0.28 | 0.31 | 0.94 | 0.84 | 0.83 |
| ADOPT6 | 0.36 |
| 0.02 | 0.23 | 0.36 | 0.39 | −0.21 |
|
| 0.42 | 0.06 | 0.32 | 0.71a | 0.66a | 0.71a |
| ADOPT7 | 0.19 |
| −0.26 | 0.20 | 0.19 |
| 0.09 | 0.15 |
| 0.54 | 0.20 | 0.16 | 0.45a | 0.30a | 0.63a |
| ADOPT8 | 0.34 |
| 0.00 | 0.25 | 0.47 |
| 0.16 | 0.15 | 0.50 |
| 0.24 | 0.21 | 0.70a | 0.61a | 0.59a |
| ORGAN1 | 0.06 |
| 0.12 | 0.01 |
| 0.40 | 0.11 | −0.06 |
| 0.50 | 0.28 | 0.17 | 0.98 | 0.63a | 0.69a |
| ORGAN2 | 0.07 |
| 0.17 | −0.05 |
| 0.48 | 0.29 | −0.02 |
| 0.42 | 0.35 | 0.20 | 0.97 | 0.74a | 0.60a |
| ORGAN3 | 0.08 |
| 0.17 | 0.12 | 0.00 |
| 0.12 | 0.13 | 0.17 |
| 0.12 | 0.20 | 0.92 | 0.95 | 0.95 |
| ORGAN4 | 0.22 |
| −0.06 | 0.13 | 0.45 |
| 0.36 | −0.08 |
| 0.48 | 0.31 | 0.19 | 0.89 | 0.78a | 0.65a |
| ORGAN5 | 0.17 |
| 0.19 | 0.00 | 0.15 |
| 0.20 | 0.03 | 0.37 |
| 0.27 | 0.16 | 0.93 | 0.97 | 0.87 |
| ORGAN6 | 0.09 |
| 0.17 | −0.05 | 0.37 |
| 0.24 | 0.16 | 0.50 |
| 0.26 | 0.19 | 0.96 | 0.81 | 0.76a |
| ORGAN7 | 0.21 | 0.02 | 0.05 |
| 0.19 |
| 0.01 | 0.37 | 0.12 |
| 0.10 | 0.40 | 0.05a | 0.73a | 0.85 |
| ORGAN8 | 0.33 |
| 0.13 | 0.26 | 0.42 |
| 0.35 | 0.29 | 0.36 |
| 0.40 | 0.38 | 0.53a | 0.64a | 0.65 |
| INNOV1 | 0.20 | −0.03 |
| 0.08 | 0.19 | 0.09 |
| 0.41 | 0.22 | 0.19 |
| 0.28 | 0.97 | 0.79a | 0.87 |
| INNOV2 | 0.17 | 0.08 |
| 0.14 | 0.33 | 0.07 |
| 0.39 | 0.41 | 0.18 |
| 0.33 | 0.96 | 0.85 | 0.80 |
| INNOV3 | 0.08 | 0.09 |
| 0.11 | −0.06 | 0.23 |
| 0.26 | 0.26 | 0.22 |
| 0.32 | 0.97 | 0.83 | 0.85 |
| INNOV4 | −0.20 | 0.19 |
| −0.03 | −0.02 | 0.20 |
| 0.22 | 0.22 | 0.28 |
| 0.34 | 0.89 | 0.86 | 0.81 |
| INNOV5 | 0.15 | 0.18 |
| 0.26 | 0.18 | 0.17 |
| 0.32 | 0.41 | 0.28 |
| 0.42 | 0.87 | 0.83 | 0.63a |
| INNOV6 | 0.04 | 0.08 | 0.16 |
| 0.32 | −0.07 | 0.22 |
| 0.34 | −0.05 | 0.42 |
| 0.34a | 0.56a | 0.64a |
| COMM1 | −0.03 | 0.30 | 0.33 |
| −0.01 | 0.23 | 0.28 |
| 0.28 | 0.22 | 0.32 |
| 0.72a | 0.87 | 0.76a |
| COMM2 | −0.06 | −0.05 | −0.01 |
| 0.10 | 0.10 | 0.20 |
| 0.30 | 0.23 | 0.25 |
| 1.00 | 0.85 | 0.80 |
| COMM3 | 0.08 | 0.11 | 0.38 |
| 0.11 | 0.10 | 0.29 |
| 0.28 | 0.33 | 0.31 |
| 0.84 | 0.83 | 0.75a |
| COMM4 | 0.14 | 0.03 | 0.13 |
| 0.01 | 0.08 | 0.15 |
| 0.13 | 0.33 | 0.18 |
| 0.93 | 0.94 | 0.85 |
| COMM5 | −0.05 | 0.02 | −0.05 |
| 0.05 | 0.07 | 0.16 |
| 0.17 | 0.18 | 0.26 |
| 0.99 | 0.92 | 0.86 |
| COMM6 | 0.13 | 0.28 |
| 0.29 | 0.23 | 0.22 | 0.28 |
| 0.45 | 0.20 | 0.27 |
| 0.46a | 0.49a | 0.66a |
Major loadings are in italics
ADOPT Characteristics of the adopter: the clinician’s research values, skills, and awareness’, ORGAN characteristics of the organisation: setting barriers and limitations, INNOV characteristics of the innovation: qualities of the research, COMM characteristics of the communication: presentation and accessibility of the research
aLower than ideal congruence coefficient
Final PCA loadings with procrustes transformation by country
| Item | Australia | United Kingdom | Taiwan | Procrustes congruence | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | AUS | UK | TAI | |
| ADOPT1 |
| 0.15 | 0.07 | 0.01 |
| 0.32 | 0.14 | 0.18 |
| 0.21 | 0.21 | 0.22 | 0.97 | 0.85 | 0.84 |
| ADOPT2 |
| 0.19 | 0.06 | 0.08 |
| 0.26 | 0.11 | 0.20 |
| 0.21 | 0.24 | 0.23 | 0.96 | 0.88 | 0.82 |
| ADOPT3 |
| 0.25 | 0.12 | −0.03 |
| 0.25 | 0.25 | 0.06 |
| 0.26 | 0.25 | 0.16 | 0.93 | 0.89 | 0.81 |
| ADOPT5 |
| 0.20 | 0.14 | 0.05 |
| 0.43 | 0.17 | 0.07 |
| 0.25 | 0.32 | 0.26 | 0.93 | 0.81 | 0.75a |
| ORGAN1 | 0.11 |
| 0.08 | 0.01 | 0.32 |
| −0.16 | 0.29 |
| 0.53 | 0.26 | 0.21 | 0.99 | 0.87 | 0.78a |
| ORGAN2 | 0.13 |
| 0.16 | −0.09 | 0.32 |
| 0.04 | 0.18 | 0.46 |
| 0.34 | 0.23 | 0.95 | 0.91 | 0.81 |
| ORGAN3 | 0.07 |
| 0.11 | 0.16 | 0.06 |
| 0.24 | −0.03 | 0.14 |
| 0.13 | 0.23 | 0.95 | 0.90 | 0.96 |
| ORGAN4 | 0.26 |
| −0.06 | 0.14 | 0.25 |
| 0.14 | 0.12 | 0.54 |
| 0.28 | 0.23 | 0.91 | 0.92 | 0.78a |
| ORGAN5 | 0.21 |
| 0.13 | 0.01 | 0.10 |
| 0.19 | −0.01 | 0.31 |
| 0.26 | 0.18 | 0.96 | 0.94 | 0.93 |
| ORGAN6 | 0.13 |
| 0.12 | −0.03 | 0.35 |
| 0.25 | −0.01 | 0.46 |
| 0.24 | 0.21 | 0.98 | 0.81 | 0.87 |
| INNOV1 | 0.15 | −0.01 |
| 0.03 | 0.22 | 0.14 |
| 0.34 | 0.22 | 0.17 |
| 0.26 | 0.97 | 0.80 | 0.91 |
| INNOV2 | 0.15 | 0.09 |
| 0.08 | 0.29 | 0.21 |
| 0.43 | 0.42 | 0.17 |
| 0.28 | 0.97 | 0.74a | 0.83 |
| INNOV3 | 0.10 | 0.09 |
| 0.08 | −0.07 | 0.27 |
| 0.15 | 0.25 | 0.21 |
| 0.26 | 0.98 | 0.95 | 0.89 |
| INNOV4 | −0.20 | 0.25 |
| −0.03 | −0.04 | 0.28 |
| 0.14 | 0.21 | 0.26 |
| 0.31 | 0.91 | 0.95 | 0.87 |
| INNOV5 | 0.15 | 0.16 |
| 0.24 | 0.28 | 0.23 |
| −0.04 | 0.40 | 0.29 |
| 0.37 | 0.89 | 0.90 | 0.70a |
| COMM2 | −0.05 | 0.00 | −0.02 |
| 0.08 | 0.09 | 0.14 |
| 0.33 | 0.16 | 0.30 |
| 1.00 | 0.96 | 0.80 |
| COMM3 | 0.11 | 0.11 | 0.41 |
| 0.17 | 0.07 | 0.36 |
| 0.30 | 0.27 | 0.36 |
| 0.85 | 0.86 | 0.76a |
| COMM4 | 0.16 | 0.01 | 0.16 |
| 0.38 | −0.16 | 0.08 |
| 0.13 | 0.25 | 0.21 |
| 0.96 | 0.89 | 0.89 |
| COMM5 | −0.06 | 0.05 | 0.00 |
| 0.28 | −0.03 | 0.26 |
| 0.18 | 0.15 | 0.29 |
| 0.99 | 0.82 | 0.88 |
Major loadings are in italics
ADOPT characteristics of the adopter: the clinician’s research values, skills, and awareness, ORGAN characteristics of the organisation: setting barriers and limitations, INNOV characteristics of the innovation: qualities of the research, COMM characteristics of the communication: presentation and accessibility of the research
aLower than ideal congruence coefficient
Fig. 1Scree plot for components by country
Cross-cultural procrustes congruence coefficients
| Item | Australia–United Kingdom | Australia–Taiwan | United Kingdom–Taiwan |
|---|---|---|---|
| ADOPT1 | 0.94 | 0.94 | 1.00 |
| ADOPT2 | 0.97 | 0.94 | 0.98 |
| ADOPT3 | 0.97 | 0.96 | 0.98 |
| ADOPT5 | 0.96 | 0.93 | 0.98 |
| ORGAN1 | 0.88 | 0.86 | 0.86 |
| ORGAN2 | 0.93 | 0.89 | 0.95 |
| ORGAN3 | 0.89 | 0.99 | 0.90 |
| ORGAN4 | 0.94 | 0.89 | 0.95 |
| ORGAN5 | 0.98 | 0.98 | 0.96 |
| ORGAN6 | 0.92 | 0.93 | 0.96 |
| INNOV1 | 0.86 | 0.94 | 0.96 |
| INNOV2 | 0.87 | 0.95 | 0.95 |
| INNOV3 | 0.96 | 0.97 | 0.94 |
| INNOV4 | 0.97 | 0.86 | 0.95 |
| INNOV5 | 0.91 | 0.93 | 0.86 |
| COMM2 | 0.95 | 0.74a | 0.89 |
| COMM3 | 1.00 | 0.95 | 0.95 |
| COMM4 | 0.96 | 0.93 | 0.81 |
| COMM5 | 0.77a | 0.86 | 0.95 |
aLess than ideal congruence coefficient
Statements for 19 item BARRIERS Scale
| Item code | Item content |
|---|---|
| ADOPT1 | The clinician does not see the value of research for practice |
| ADOPT2 | The clinician sees little benefit for self |
| ADOPT3 | The clinician is unwilling to change/try new ideas |
| ADOPT5 | The clinical feels the benefits of changing practice will be minimal |
| ORGAN1 | Administration will not allow implementation |
| ORGAN2 | Physicians will not cooperate with implementation |
| ORGAN3 | There is insufficient time on the job to implement new ideas |
| ORGAN4 | Other staff are not supportive of implementation |
| ORGAN5 | The facilities are inadequate for implementation |
| ORGAN6 | The clinician does not feel she/he has enough authority to change client care procedures |
| INNOV1 | The research has methodological inadequacies |
| INNOV2 | The conclusion drawn from the research is not justified |
| INNOV3 | The research has not been replicated |
| INNOV4 | The literature reports conflicting results |
| INNOV5 | The clinician is uncertain whether to believe the results of the research |
| COMM2 | Research reports/articles are not readily available |
| COMM3 | The research is not reported clearly and readably |
| COMM4 | Statistical analyses are not understandable |
| COMM5 | The relevant literature is not compiled in one place |
Items adapted from Funk et al. [10]
Cronbach’s α reliability coefficients for adapted scales by country
| Adapted scale | Australia | United Kingdom | Taiwan |
|---|---|---|---|
| ADOPT | 0.80 | 0.90 | 0.92 |
| ORGAN | 0.80 | 0.83 | 0.91 |
| INNOV | 0.79 | 0.85 | 0.92 |
| COMM | 0.68 | 0.66 | 0.86 |
Pearson’s correlation for original and adapted scales by country
| Adapted scales | |||
|---|---|---|---|
| Australia | United Kingdom | Taiwan | |
| Original | |||
| ADOPT | 0.91 | 0.95 | 0.95 |
| ORGAN | 0.96 | 0.98 | 0.98 |
| INNOV | 0.96 | 0.98 | 0.99 |
| COMM | 0.93 | 0.94 | 0.97 |
All correlations were significant p < 0.001